Your browser doesn't support javascript.
loading
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes.
Molitch, Mark E; Adler, Amanda I; Flyvbjerg, Allan; Nelson, Robert G; So, Wing-Yee; Wanner, Christoph; Kasiske, Bertram L; Wheeler, David C; de Zeeuw, Dick; Mogensen, Carl E.
Afiliación
  • Molitch ME; Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Adler AI; Institute of Metabolic Science, Addenbrooke's Hospitals, Cambridge, UK.
  • Flyvbjerg A; Aarhus University, Aarhus C, Denmark.
  • Nelson RG; National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona, USA.
  • So WY; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
  • Wanner C; University Hospital of Würzburg, Würzburg, Germany.
  • Kasiske BL; Hennepin County Medical Center, Minneapolis, Minnesota, USA.
  • Wheeler DC; University College London, London, UK.
  • de Zeeuw D; University Medical Center Groningen, Groningen, The Netherlands.
  • Mogensen CE; Aarhus University Hospital and Aarhus University, Aarhus, Denmark.
Kidney Int ; 87(1): 20-30, 2015 Jan.
Article en En | MEDLINE | ID: mdl-24786708
ABSTRACT
The incidence and prevalence of diabetes mellitus (DM) continue to grow markedly throughout the world, due primarily to the increase in type 2 DM (T2DM). Although improvements in DM and hypertension management have reduced the proportion of diabetic individuals who develop chronic kidney disease (CKD) and progress to end-stage renal disease (ESRD), the sheer increase in people developing DM will have a major impact on dialysis and transplant needs. This KDIGO conference addressed a number of controversial areas in the management of DM patients with CKD, including aspects of screening for CKD with measurements of albuminuria and estimated glomerular filtration rate (eGFR); defining treatment outcomes; glycemic management in both those developing CKD and those with ESRD; hypertension goals and management, including blockers of the renin-angiotensin-aldosterone system; and lipid management.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Nefropatías Diabéticas Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Kidney Int Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Nefropatías Diabéticas Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Kidney Int Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos